| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 01/26/2006 | US20060019249 Diagnostic conjugate useful for intracellular imaging and for differentiating between tumor-and non-tumor cells |
| 01/26/2006 | US20060018956 Dermal application system for aminolevulinic acid-derivatives |
| 01/26/2006 | US20060018914 Novel antibody conjugates reactive with human carcinomas |
| 01/26/2006 | US20060018837 Pharmaceutical compositions and methods for the prevention of drug misuse |
| 01/26/2006 | US20060018835 Nanoparticles with inorganic core and methods of using them |
| 01/26/2006 | US20060018834 Imaging sexual response |
| 01/26/2006 | US20060018833 Method and system for screening compounds for muscular and/or neurological activity in animals |
| 01/26/2006 | US20060018832 Methods of marking and testing pharmaceutical products |
| 01/26/2006 | US20060018829 Cellular receptors utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment |
| 01/26/2006 | US20060018828 Mixing a sterol or a polyether modified phospholipid capable of forming a liposome with a supercritical carbon dioxide, contacting water-soluble nonionic iodine compound with phospholipid to form a liposome containing vesicles including the iodine compound; chlorine-free solvent |
| 01/26/2006 | US20060018825 Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change |
| 01/26/2006 | CA2573783A1 Cyanine dyes conjugated with antibodies for the diagnosis of micrometastasis |
| 01/26/2006 | CA2570998A1 Improved efficacy of active immunotherapy by integrating diagnostic with therapeutic methods |
| 01/26/2006 | CA2570909A1 Method of determining performance of an antiperspirant composition |
| 01/25/2006 | EP1619501A1 Use of cyanine dyes for the diagnosis of disease associated with angiogenesis |
| 01/25/2006 | EP1618899A2 Method of measuring physiological function |
| 01/25/2006 | EP1618898A2 Methods for regulating angiogenesis |
| 01/25/2006 | EP1618190A2 Pathophysiology associated with a single gene (mass1) mutation underlying the robust audiogenic seizure phenotype in frings mice |
| 01/25/2006 | EP1618184A2 Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
| 01/25/2006 | EP1617864A2 Epha2 and non-neoplastic hyperproliferative cell disorders |
| 01/25/2006 | EP1617819A1 Radioactively marked microparticles, method for the production thereof and use of the same |
| 01/25/2006 | EP1474430B1 Bi-functionalised metallocenes use for marking biological molecules |
| 01/25/2006 | EP1066067B1 Gynecological embolization and kit therefor |
| 01/25/2006 | EP0697872B1 Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| 01/25/2006 | CN1724076A Nuclear magnetic resonance imaging contrast medium, and its prepn. method |
| 01/25/2006 | CN1724075A Alzheimer's disease model mouse latent infected by human cytomegalovirus, and its establishing mehtod |
| 01/25/2006 | CN1724074A Cancerigenic suspension for inducing mouse lung squamous cancer, and its prepn. method |
| 01/24/2006 | US6989443 Carboranylporphyrins and uses thereof |
| 01/24/2006 | US6989278 administering alcohol and an agent such as concanavalin A as a model for identification of therapeutic substances; Chinese herb CH-100 proved useful in treatment of alcohol-induced hepatitis |
| 01/24/2006 | US6989147 Tumor necrosis factor receptor protein for use in the treatment of arthritis |
| 01/24/2006 | US6989141 Administering contrast agent comprising stabilized microbubbles which comprises physiologically acceptable gas selected from freons, halogenated hydrocarbons, and fluorinated gases and surfactant; ultrasonically imaging |
| 01/24/2006 | US6989140 Methods for cancer imaging |
| 01/24/2006 | US6989139 Matrix metalloproteinase inhibitors |
| 01/24/2006 | CA2171954C Method for the preparation of high purity substituted benz[e] indoles and the alkaline salts thereof |
| 01/19/2006 | US20060014160 Determining whether or not mammary gland sodium/iodide symporter (mgNIS) is expressed in breast tissue of the subject, whereinexpression of mgNIS in the breast tissue is detected using an antibody, specific for mgNIS, expression of mgNIS in the breast tissue of is indicative of breast cancer presence |
| 01/19/2006 | US20060013774 Porphyrin compounds and their use in high-field MRI |
| 01/19/2006 | US20060013771 Method of preparing gas-filled polymer matrix microparticles useful for echographic imaging |
| 01/19/2006 | US20060013770 Method for screening for compounds as potential sedatives or anxiolytics |
| 01/19/2006 | US20060013769 Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein |
| 01/19/2006 | US20060013768 Injection of a radioactive dye for sentinel lymph node identification |
| 01/18/2006 | EP1616883A2 Antibodies against VLA-4 |
| 01/18/2006 | EP1616193A1 MULTIPLEX SCREENING FOR LYSOSOMAL STORAGE DISORDERS (LSDs) |
| 01/18/2006 | EP1615559A2 Method to determine the spatial distribution of magnetic particles and magnetic particle administering compositions |
| 01/18/2006 | EP1615558A2 Method for the spatially resolved determination of physical, chemical and biological properties or state variables |
| 01/18/2006 | EP1615556A2 Method of determining state variables and changes in state variables |
| 01/18/2006 | EP1615555A2 Method for spatially resolved determination of magnetic particle distribution in an area of examination |
| 01/18/2006 | EP1615544A2 Arrangement and method for the spatially resolved determination of state variables in an examination area |
| 01/18/2006 | EP1615494A1 Non-human mammals and animal cells containing a mutated alpha2/delta gene |
| 01/18/2006 | EP1615493A2 Non-human mammals and animal cells containing a mutated alpha2/delta1 gene |
| 01/18/2006 | CN1723043A 造影剂 Contrast agents |
| 01/18/2006 | CN1723042A Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| 01/18/2006 | CN1722953A Methods for treating cancer by inhibiting Wnt signaling |
| 01/18/2006 | CN1721000A Gastrointestinal ultrasonic contrast medium with echo and its preparation process |
| 01/17/2006 | US6986891 Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof |
| 01/17/2006 | US6986882 Therapy for functional dyspepsia |
| 01/17/2006 | US6986881 Identification of compounds that modify transcriptional responses to hypoxia |
| 01/17/2006 | US6986740 administering an ultrasound contrast agent such as Rose Bengal; a portion of the contrast agent being retained in tissue of interest; and imaging the tissue with ultrasound to identify the tissue |
| 01/12/2006 | WO2006004429A2 Imaging agents comprising a non- peptidic vector linked to a fluorophore via a polyethylene glycol linker |
| 01/12/2006 | WO2006002875A1 Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents |
| 01/12/2006 | WO2006002874A1 Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain 1, 4, 7, 10-tertraazacyclodecan-1, 4, 7-triacetic acid chelating moiety with polyhydroxylated substituents |
| 01/12/2006 | WO2006002873A2 1 , 4 -bis (carboxymethyl) -6- ' bis ( carboxymethyl) amino ! -6 -methyl- perhydro-1 , 4 diazepine (aazta) derivatives as ligands in high relaxivity contrast agents for use in magnetic resonance imaging (mri ) |
| 01/12/2006 | WO2005045039A3 RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/12/2006 | US20060008893 Nanoengineered biophotonic hybrid device |
| 01/12/2006 | US20060008873 Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
| 01/12/2006 | US20060008475 Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to Gb3 expressing tumors |
| 01/12/2006 | US20060008418 Packaging and method for solid dose administration of an electronic identification chip and medicaments |
| 01/12/2006 | US20060008417 Lipophilic derivatives of chelate monoamides |
| 01/12/2006 | US20060008416 High resolution metabolic brain imaging |
| 01/11/2006 | EP1615032A1 Method of detecting onset risk of encephalitis or encephalopathy |
| 01/11/2006 | EP1613358A1 Adducts between magnetic resonance shift reagents and substrates containing exchangeable protons for "cest" applications |
| 01/11/2006 | EP1613351A1 Targeted agents for both photodiagnosis and photodynamic therapy |
| 01/11/2006 | EP1613348A2 Methods for modulating angiogenesis with apelin compositions |
| 01/11/2006 | EP1161265A4 Method for the identification and removal of nits from hair |
| 01/11/2006 | EP1073476B1 Catheter for obtaining cellular material from breast ducts |
| 01/11/2006 | EP0827412B1 A method for radiolabeling a somatostatin-derived peptide analogue having one disulfide bond with a radioisotope of rhenium, and their therapeutical applications |
| 01/11/2006 | CN1720050A Improved imaging agents comprising barbituric acid derivatives |
| 01/11/2006 | CN1235569C Porous composite material granular blood vessel embolism agent |
| 01/10/2006 | US6984518 DNA construct comprising an FGF1B promoter region operably linked to an SV40 large T antigen encoding sequence |
| 01/10/2006 | US6984498 Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques |
| 01/10/2006 | US6984375 Quantitative analysis; administering to muscle of mammals |
| 01/10/2006 | US6984374 Method for the evaluation of implantable materials |
| 01/10/2006 | US6984373 For diagnosis and therapy of pathological intravascular thrombosis; for detecting, imaging, and localizing thrombi |
| 01/10/2006 | CA2351620C Nano-emulsion of 5-aminolevulinic acid |
| 01/10/2006 | CA2097997C Vitamin d compounds and method of preparing these compounds |
| 01/05/2006 | WO2006002142A2 Imaging infection with compounds that bind to thymidine kinase |
| 01/05/2006 | WO2006001986A2 Glut3 transporters expressed in cancer cells |
| 01/05/2006 | WO2006001848A2 Quantum dots as high-sensitivity optical sensors and biocompatible imaging probes, compositions thereof, and related methods |
| 01/05/2006 | WO2005074996A3 Lat1 transporter expressed in blood brain barrier cells |
| 01/05/2006 | WO2005070003A3 Abuse potential reduction in abusable substance dosage form |
| 01/05/2006 | US20060004081 Cytotoxic compounds and conjugates |
| 01/05/2006 | US20060003983 Photosensitizer and method for production thereof |
| 01/05/2006 | US20060003926 Anticancer, antitumor agents; mixture of metal, drug, peptide and carriers |
| 01/05/2006 | US20060003920 LAT1 transporters expressed in cancer cells |
| 01/05/2006 | US20060003361 SMVT transporters expressed in cancer cells |
| 01/05/2006 | US20060002860 Abuse-proofed oral dosage form |
| 01/05/2006 | US20060002859 Process for production of an abuse-proofed solid dosage form |
| 01/05/2006 | US20060002858 Concentrated X-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions |
| 01/05/2006 | US20060002857 diagnostic detection of diseases accompanied with an abnormality of calcium hydroxyapatite using in vivo imaging; contrast agent comprising a fluorescent moiety covalently linked to a bisphosphonate moiety such as, alendronate, clodronate, EB-1053, etidronate, ibandronate, incadronate, neridronate |
| 01/05/2006 | US20060002856 Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129Xe |
| 01/05/2006 | US20060002854 Conjugate of therapeutic moiety linked to peptide having the amino acid sequence CGKRK, length < 400 residues, or a conservative variant or peptidomimetic; anticarcinogenic, -tumor agents; tissue-targeted therapy; side effect reduction; binds cognate receptor; angiogenesis inhibitors |